Complete Story
 

Expanded Coverage of Bevacizumab (Avastin )

Indications

Avastin is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of:

Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment.

Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease.

Metastatic breast cancer, with paclitaxel for treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer.

Effectiveness based on improvement in progression-free survival. No data available demonstrating improvement in disease-related symptoms or survival with Avastin.

Not indicated for disease progression following anthracycline and taxane chemotherapy administered for metastatic disease.

Glioblastoma, as a single agent for patients with progressive disease following prior therapy.

Effectiveness based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Avastin.

Metastatic renal cell carcinoma with interferon alfa

For more information: CLICK HERE

Printer-Friendly Version